Immunolocalization of DMP1 and sclerostin in the epiphyseal trabecule and diaphyseal cortical bone of osteoprotegerin deicient mice

Biomedical Research

Volumn 31, Issue 5, 2010, Pages 307-318

  Masuki, Hideo ^a   Li, Minqi ^a   Hasegawa, Tomoka ^a   Suzuki, Reiko ^a   Ying, Guo ^a   Zhusheng, Liu ^a   Oda, Kimimitsu ^b   Yamamoto, Tsuneyuki ^a   Kawanami, Masamitsu ^a   Amizuka, Norio ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; DENTIN MATRIX PROTEIN 1; OSTEOPROTEGERIN; SCLEROSTIN; TARTARIC ACID;

ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE REMODELING; CELL ACTIVITY; CELL FUNCTION; CONTROLLED STUDY; CORTICAL BONE; EPIPHYSIS; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRABECULAR BONE;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; DIAPHYSES; EPIPHYSES; EXTRACELLULAR MATRIX PROTEINS; GENETIC MARKERS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MALE; MICE; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN;

MUS;

EID: 78249280330     PISSN: 03886107     EISSN: 1880313X     Source Type: Journal    
DOI: 10.2220/biomedres.31.307     Document Type: Article

References (38)

1. Aarden EM, Burger EH and Nijweide PJ (1994) Function of osteocytes in bone. J Cell Biochem 55, 287-299.
2. Amizuka N, Takahashi N, Udagawa N, Suda T and Ozawa H (1997) An ultrastructural study of cell-cell contact between mouse spleen cells and calvaria-derived osteoblastic cells in a co-culture system for psteoclast formation. Acta Histochem Cytochem 30, 351-362.
3. Amizuka N, Shimomura J, Li M, Seki Y, Oda K, Henderson JE, Mizuno A, Ozawa H and Maeda T (2003) Defective bone remodelling in osteoprotegerin-deficient mice. J Electron Microsc 52, 503-513.
4. Bélanger LF (1969) Osteocytic osteolysis. Calcif Tissue Res 4, 1-12.
5. Bodian D (1936) A new method for staining nerve ibers and nerve endings in mounted parafin section. Anat Rec 65, 89-97.
6. Bodian D (1937) The staining of parafin sections of nerve tissue with activated protagol. The role of ixatives. Anat Rec 69, 153-162.
7. Burger EH and Klein-Nulend J (1999) Mechanotransduction in bone role of the lacuno-canalicular network. FASEB J 13, 101-112.
8. Burger EH (1995) Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J 9, 441-445.
9. Doty SB (1981) Morphological evidence of gap junctions between bone cells. Calcif Tissue Int 33, 509-512.
10. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF and White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identiies a role for osteocytes in mineral metabolism. Nat Genet 38, 1230-1231.
11. Freitas de Luis HP, Li M, Ninomiya T, Nakamura M, Ubaidus S, Oda K, Udagawa N, Maeda T, Takagi R and Amizuka N (2009) Intermittent PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos(-/-) mice. J Bone Miner Res 24, 1586-1597.
12. George A, Gui J, Jenkins NA, Gilbert DJ, Copeland NG and Veis A (1994) In situ localization and chromosomal mapping of the AG1 (Dmp1) gene. J Histochem Cytochem 42, 1527-1531.
13. Hirose S, Li M, Kojima T, de Freitas PH, Ubaidus S, Oda K, Saito C and Amizuka N (2007) A histological assessment on the distribution of the osteocytic lacunar canalicular system using silver staining. J Bone Miner Metab 25, 374-382.
14. Klein-Nulend J, van der Plas A, Semeins CM, Ajubi NE, Frangos JA, Nijweide PJ and Burger EH (1995) Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J 9, 441-445.
15. Knothe Tate ML, Adamson JR, Tami AE and Bauer TW (2004) The osteocyte. Int J Biochem Cell Biol 36, 1-8.
16. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I and Itoh N (2003) Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278, 24113-24117;
17. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J and Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176.
18. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE and Wu D (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280, 19883-19887.
19. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL and Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoprosis. J Bone Miner Res 24, 578-588.
20. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X and He L (2009) Sclerostin mediates bone response to mechanical unloading via antagonizing Wnt/betacatenin signaling. J Bone Miner Res 24, 1641-1661.
21. Oda K, Amaya Y, Fukushi-Irie M, Kinameri Y, Ohsuye K, Kubota I, Fujimura S and Kobayashi J (1999) A general method for rapid puriication of soluble versions of glycosylphosphatidylinositol-anchored proteins expressed in insect cells: an application for human tissue-nonspeciic alkaline phosphatase. J Biochem 126, 694-699.
22. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW and Reeve J (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19, 1842-1844.
23. Shapiro F (1997) Variable conformation of GAP junctions linking bone cells: a transmission electron microscopic study of linear stacked linear, curvilinear, oval, and annular junctions. Calcif Tissue Int 61, 285-293.
24. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M and Bonucci E (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38, 261-269.
25. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R and Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319.
26. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT and Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Rev 20, 345-357.
27. Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S and Ikeda K (2007) Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5, 464-475.
28. Takahashi N, Udagawa N, Akatsu T, Tanaka H, Isogai Y and Suda T (1991) Deiciency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells. Endocrinology 128, 1792-1796.
29. Toyosawa S, Shintani S, Fujiwara T, Ooshima T, Sato A, Ijuhin N and Komori T (2001) Dentin matrix protein 1 is predominantly expressed in chicken and rat osteocytes but not in osteoblasts. J Bone Miner Res 16, 2017-2026.
30. Tsukii K, Shima N, Mochizuki S, Yamaguchi K, Kinosaki M, Yano K, Shibata O, Udagawa N, Yasuda H, Suda T and Higashio K (1998) Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun 246, 337-341.
31. Ubaidus S, Li M, Sultana S, de Freitas PH, Oda K, Maeda T, Takagi R and Amizuka N (2009) FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J Electron Microsc 58, 381-392.
32. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P and Löwik CW (2004) Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199, 805-814.
33. van Bezooijen RL, ten Dijke P, Papapoulos SE and Löwik CW (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16, 319-327.
34. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK and Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284, 10890-10900.
35. Weinbaum S, Cowin SC and Zeng Y (1994) A model for the excitation of osteocytes by mechanical loading-induced bone luid shear stresses. J Biomech 27, 339-360.
36. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH and Mumm S (2002) Osteoprotegerin deiciency and juvenile Paget's disease. N Engl J Med 347, 175-184.
37. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME and Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22, 6267-6276.
38. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N and Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95, 3597-3602.